色多多下载官方版_色多多app最新版下载_色多多深夜福利免费观看_色多多网站入口官方版下载

TEL:020-31701980      FAX:020-31701979     E-mail:sales@mx008.com
China Mingxuan
Service Hotline:020-3171980
搜索

News
MX trends
industry trends
fair information
 
Micro-channel
 
Information details You are here:Home >> News >> industry trends
 
Eight drug firms to be included in the new three board top enterprise's value
 
Author:中國銘鉉 企劃部  Release Time:2017-3-4 9:51:51  Number Browse:578
 
Medical network on March 3 - by the end of February 28, 2017, the new three board a total of 10757 listed companies, dig new three board Mr Institute create the new three board enterprise value in February 2017 TOP 100 list, on the threshold of 3.519 billion yuan. 
 
The list of 100 companies total market value of 907.511 billion yuan, a 1.6% month-on-month growth in January 2017. 
 
Medical mobile news, according to statistics, the pharmaceutical industry listed companies and new industry, the pharmaceutical industry, jun real biological, into large creature, the kernel will creatures, zhijiang, macro economic hall, sunny and pharmacy. The eight companies the market value of total is 65.37 billion yuan, accounting for 7.2% of the TOP 100 list of enterprise market capitalisation. Among them: 
 
Two level of market value of billions of enterprises: new industry (18.464 billion yuan), the pharmaceutical industry (15.608 billion yuan); 
 
Value in 50-10 billion yuan of business has three: sovereign real biological (7.167 billion yuan), into the biological (6.776 billion yuan), the kernel will (5.88 billion yuan); 
 
Market value of less than 5 billion yuan of business has three: zhijiang (4 billion yuan), macro economic hall (3.95 billion yuan), sanli pharmaceutical (3.525 billion yuan). 
 
The following eight drug firms to summary: 
 
New industries 
 
New industry (shenzhen new industries biomedical engineering co., LTD.) co., LTD was established in August 2012, in July 2014 in listed shares transfer system, mainly engaged in automatic chemiluminescence immune analyzer and reagent. 
 
Close all pharmaceutical co. 
 
Close all pharmaceutical and all pharmaceutical co., LTD. (Shanghai) was established in January 2003, completed in December 2011 the share reform, committed to technological innovation and commercialization of global pharmaceutical process, for the international mainstream medicine enterprise provide innovative drug research and development production outsourcing services. 
 
Your real biological 
 
On December 27, 2012, the company formerly Shanghai jun real biological medicine science and technology co., LTD. Was set up. On May 5, 2015, the company name changed to "Shanghai gentleman real biological medicine science and technology co., LTD.". Mainly engaged in biological medicine research and development, and provide the related technology development, technology consultation, technology transfer, technical services. 
 
Into large biological 
 
Into large biological (liaoning cheng da co., LTD.) co., LTD was established in November 2010, listed on shares transfer system in December 2014, the main business for the production and sales people with rabies vaccine and people with je inactivated vaccines. 
 
The kernel will creatures 
 
Kernel will biological (Shanghai ren will biological pharmaceutical co., LTD.) co., LTD was established in January 2014, listed on shares transfer system in August 2014, mainly engaged in innovative biotech drugs research and development, production and sales. 
 
Zhijiang biological 
 
Zhijiang biological zhijiang (Shanghai biological technology co., LTD.) was founded in 2005, on April 18, is mainly engaged in molecular diagnostics research and development, production and sales. 
 
Macro economy class 
 
Macro economic hall pharmaceutical group co., LTD. (shandong macro economic hall) is mainly engaged in musk ketone, proprietary Chinese medicine, montmorillonite and gelatin apis and other health products research and development, production and sales. 
 
Sanli pharmaceutical 
 
Sanli pharmaceutical (guizhou sunny pharmaceutical co., LTD.) was established in September 1995, completed in January 2015 the share reform, mainly engaged in the throat diseases, cardiovascular disease and other diseases of proprietary Chinese medicine research and development, production and sales. 

 
Previous article:"Much starker choices-and graver consequences-in" promoting equal basic public services planning
Next article:《Registered medical device network security technical review guidelines 》Interpretation of the
 
Log in  Website Map All right reserved by China Mingxuan, Guangzhou ICP #16026227
    

粵公網安備 44011202000029號